Monopar Therapeutics (NASDAQ:MNPR) Sets New 12-Month High - What's Next?

Key Points

• Monopar Therapeutics hit a new 52-week high, trading as high as $115 intraday before ending near $111.29, reflecting a sharp recent run in the stock.
• Analyst sentiment is generally positive, with the stock carrying an average Buy rating and a consensus target price of $108.75; BTIG recently raised its target to $117.
• The company recently beat quarterly earnings expectations, posting ($0.46) EPS versus the expected ($0.87), while institutional investors have also been adding to positions.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s stock price reached a new 52-week high on Monday . The stock traded as high as $115.00 and last traded at $111.2940, with a volume of 10976 shares trading hands. The stock had previously closed at $111.12.

Analyst Ratings Changes

MNPR has been the topic of a number of recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. UBS Group set a $105.00 price objective on shares of Monopar Therapeutics in a report on Monday, June 29th. BTIG Research increased their target price on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Chardan Capital restated a "buy" rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Finally, Piper Sandler set a $105.00 price target on Monopar Therapeutics in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $108.75.

Monopar Therapeutics Stock Down 2.4%

The firm has a market cap of $726.51 million, a price-to-earnings ratio of -56.96 and a beta of 1.46. The company's 50-day moving average price is $75.72 and its 200-day moving average price is $65.12.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. Analysts predict that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently made changes to their positions in MNPR. Goldman Sachs Group Inc. purchased a new stake in shares of Monopar Therapeutics during the first quarter worth approximately $673,000. Jane Street Group LLC acquired a new stake in Monopar Therapeutics during the 1st quarter worth $377,000. Geode Capital Management LLC grew its holdings in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after buying an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at about $209,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.